Only one injection required per month? Pfizer (PFE.US) acquires Metsera (MTSR.US) for $7.3 billion, betting on long-acting insulin therapy.

According to the Zhitong Financial APP, it is reported that Pfizer (PFE.US) is about to acquire the start-up company Metsera (MTSR.US) for $7.3 billion. This move is aimed at strengthening its product line layout after its highly anticipated weight loss drug project suffered setbacks recently. According to informed sources, the transaction may be officially announced as early as Monday. Pfizer will acquire Metsera for $47.50 per share in cash, and will also pay an additional $22.50 per share if certain performance milestones are met. This offer represents a significant premium compared to Metsera's closing price of $33.32 per share on last Friday. As of non-working hours, neither party has commented on this.